II. Indications
- FDA Approved (often combined with other agents)
- Breast Cancer
- Gastric Cancer
- Head and Neck Cancer (Squamous Cell Carcinoma)
- Non-Small Cell Lung Cancer
- Prostate Cancer (metastatic, Hormone-refractory)
- Off-Label
- Melanoma
- Non-Hodgkin's Lymphoma
- Ovarian Cancer
- Pancreatic Cancer
- Sarcoma (soft tissue)
- Small Cell Lung Cancer
- Urothelial Cancer
III. Mechanism
- See Mitotic Inhibitor Chemotherapy
- Docetaxel is a semi-synthetic, second-generation Taxane
- Derived from extract of the European yew tree (Taxus baccata)
- Docetaxel has antineoplastic activity (Taxane)
- Binds and stabilizes tubulin
- Inhibits microtubule disassembly
- Results in Cell Cycle arrest in G2/M phase
- Docetaxel inhibits proangiogenic factors (new vessel formation promotors)
- Inhibits Vascular Endothelial Growth Factor (VEGF)
- Docetaxel induces inflammatory response
- Stimulates inflammatory mediators
IV. Medications
- Available in both IV and IV concentrate solutions: 20 mg to 200 mg vials
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
- Edema
- Fatigue
- Hepatotoxicity
-
Hypersensitivity Reaction (severe)
- Subsequent reactions after an initial may grow in severity
- Cross reacts with Paclitaxel Hypersensitivity
- Impaired future fertility
- Intoxication (Alcohol related)
- Myelosuppression (Bone Marrow Suppression)
- Neutropenia (severe)
-
Peripheral Neuropathy
- Less than Paclitaxel
- Paresthesias
- Skin Changes
- Extremity erythema
- Nail pigmentation changes
- Alopecia (may be irreversible)
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
VIII. Drug Interactions
-
CYP3A4 Inhibitors or substrates
- Increases Docetaxel serum concentrations
IX. Resources
- Docetaxel Injection Solution (DailyMed)
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI_NCI-GLOSS) | A drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Docetaxel is a type of mitotic inhibitor. |
| Definition (NCI) | A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04) |
| Definition (PDQ) | A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41657&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41657&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1526" NCI Thesaurus) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C067311 |
| SnomedCT | 108806006, 386918005 |
| English | Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, docetaxol, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, [2aR-[2a Alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester, docetaxel, docetaxel (medication), docetaxel [Chemical/Ingredient], Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-y, DOCETAXEL, DOCEtaxel, DOCEtaxel (obsolete), [2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester, docetaxel hydrate, N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol, docetaxel trihydrate, Docetaxel, Docetaxel (product), Docetaxel (substance) |
| Spanish | docetaxel (producto), docetaxel (sustancia), docetaxel |
